Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT04416451Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in marginal zone lymphoma (MZL), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2021; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04416451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416451.